Combination of Tiragolumab, Atezolizumab, and Chemotherapy in Treating Advanced Nonsquamous Non–Small Cell Lung Cancer: A Phase Study
Overview
The SKYSCRAPER-06 trial evaluated the efficacy and safety of tiragolumab combined with atezolizumab and chemotherapy versus standard pembrolizumab plus chemotherapy in patients with untreated locally advanced or metastatic nonsquamous NSCLC. The trial was a phase 2/3, double-blind, placebo-controlled study, and results indicated no significant improvement in progression-free or overall survival with the combination treatment compared to the standard regimen.
Background
Non–small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and is a leading cause of cancer mortality. Nonsquamous types comprise around 75% of NSCLC cases. Current first-line treatments involve PD-L1/PD-1 inhibitors combined with chemotherapy, which have shown improved survival compared to chemotherapy alone. However, many patients still experience disease progression, highlighting the need for more effective therapies.
Data Highlights
The SKYSCRAPER-06 trial did not demonstrate a statistically significant improvement in progression-free survival or overall survival with the combination treatment compared to standard pembrolizumab plus chemotherapy.
Key Findings
The SKYSCRAPER-06 trial was a phase 2/3, double-blind, placebo-controlled study.
Patients included were those with untreated locally advanced or metastatic nonsquamous NSCLC.
Interim safety and efficacy reviews confirmed the prespecified threshold for expansion was met.
The combination of tiragolumab, atezolizumab, and chemotherapy did not show improved survival compared to pembrolizumab plus chemotherapy.
Despite initial promise in early-phase trials, the combination treatment failed to demonstrate clinical benefit.
Clinical Implications
The findings from the SKYSCRAPER-06 trial indicate that the combination of tiragolumab with atezolizumab and chemotherapy did not provide additional benefits over existing standard treatments.
Conclusion
The SKYSCRAPER-06 trial results indicate that the combination of tiragolumab, atezolizumab, and chemotherapy does not improve outcomes in advanced nonsquamous NSCLC compared to standard therapies.
by Mark A. Socinski, Rolf Stahel, Dae Ho Lee, Federico Cappuzzo, Makoto Nishio, Christine M. Lovly, Ozgur Ozyilkan, Qingshan Li, Melissa Johnson, Edward B. Garon, Saadettin Kilickap, Flavio Augusto Ferreira da Silva, Jorge Alatorre-Alexander, Raymond Meng, Reena Amin, Christina Matheny, Sarah Troutman, Xiaohui Wen, Namrata S. Patil, Wei Zou, Delvys Rodriguez-Abreu
The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.
